Novartis India Enters Retina Segment via Exclusive Distribution Deal with NHPL
Novartis India Ltd 路 Others (Uncategorized) 路 08 Sept 2026, 3:23 pm
Novartis India Enters Retina Segment via Exclusive Distribution Deal with NHPL Novartis India Limited executed an Exclusive Promotion and Distribution Agreement on 8th Sep'26 with Novartis Healthcare Private Limited (NHPL) to exclusively market and distribute NHPL鈥檚 retina portfolio鈥攃omprising Accentrix (ranibizumab) and Pagenax (brolucizumab)鈥攊n India. Under the terms, the company will pay an upfront consideration of INR 10 Crores to NHPL. The transaction marks Novartis India's strategic entry into the ophthalmology therapy segment while expanding its commercial pharmaceutical portfolio. The agreement involves no promoter group relationship and is not classified as a related-party transaction.
Original exchange filing (PDF)
More announcements from Novartis India Ltd
- Transcript of the Earnings Call held on Wednesday, November 04, 2026. 路 06 Nov 2026
- Submission of the Letter of Offer in connection with the proposed Rights Issue of the Partly Paid-up Equity Shares of the Company. 路 06 Nov 2026
- Intimation is hereby given that the record date for determining the rights entitlement for the Rights Issue of partly paid-up shares of the Company shall be Wednesday, November 11, 2026. 路 05 Nov 2026
- Outcome of the Board Meeting held today i.e. November 04, 2026 路 05 Nov 2026
- Outcome of the meeting of the Rights Issue Committee held today i.e. November 04, 2026 路 05 Nov 2026
- Intimation of the Audio Recording of the Earnings Call for the Unaudited Financial Results for the quarter and half year ended September 30, 2026, held today i.e. on Wednesday, November 04, 2026. 路 04 Nov 2026
- Intimation of the Integrated Unaudited Financial Results for the quarter and half year ended September 30, 2026. 路 04 Nov 2026
- Press Release - Unaudited Financial Results for the quarter and half year ended September 30, 2026. 路 04 Nov 2026
